PROF ALAN TROUNSON’S $US3bn STEM CELL INSTITUTE
November 1st 2008 01:57
Tuesday October 28, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS DOWN: PRANA UP 21%, OPTISCAN DOWN 25%
* ALCHEMIA SLASHES 60% OF STAFF TO REDUCE CASH BURN
* PROF ALAN TROUNSON’S $US3bn STEM CELL INSTITUTE
* LIVING CELL: ‘3-5 YEARS TO MARKET’
* VENTRACOR TIGHTENS BELTS; $12m PLACEMENT, SHARE PLAN
* TISSUE THERAPIES VOTES ON CONVERTIBLE NOTES; CEO OPTIONS
* METABOLIC AGM VOTES ON POLYNOVO ACQUISITION; NAME CHANGE
* RESONANCE VOTES ON $10k M-D SHARES, INCENTIVE OPTIONS
* SOLBEC VOTES ON LASER CENTRE, NAME CHANGE, DIRECTORS
* PORTLAND CEO JOHN BRASSIL RESIGNS
* ELLEX REPLACES CFO, COMPANY SECRETARY
* VIRALYTICS APPOINTS GAVIN CLARK TO BUSINESS DEVELOPMENT
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
PROF ALAN TROUNSON
The president of the California Institute for Regenerative Medicine, Prof Alan Trounson, says stem cell research will lead to therapies for a diverse range of indications.
Prof Trounson gave the Prof Nancy Millis Oration at Ausbiotech’s 2008 Conference in Melbourne and said opposition to embryonic stem cell research by US President George W Bush encouraged Californians to support Proposition 71 on “the right to conduct research not supported by Federal funding”.
Prof Trounson said 60 percent of Californian voters supported the Proposition and his Institute was the holder of a $US3 billion stem cell research fund.
“People now return my calls, which is an experience I didn’t always have,” Prof Trounson said.
He said his Institution had a mission statement to take stem cell research from discovery to the clinic.
He said stem cell research could lead to therapies for glioblastoma, Alzheimer’s disease, Parkinson’s disease and motor neuron disease, along with spinal cord repair, retinal epithelial repair, beta islet cells for diabetes and cardiac muscle progenitors.
He said the Institute was providing grants and loans and expected a three-fold return from successful development to fund future work, with no intellectual property ownership.
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 34 |
| Vote |
Add To: 
subscribe to this blog